Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia
Status:
Completed
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
Allogeneic stem cell transplantation (AlloSCT) followed by targeted immune therapy Gemtuzumab
Ozogamicin patients with acute myeloid leukemia (AML)/juvenile myelomonocytic leukemia
(JMML)/myelodysplastic syndromes (MDS) will be safe and well tolerated.